CVA Family Office’s MoonLake Immunotherapeutics MLTX Stock Holding History

CVA Family Office’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17K	Hold	60	–	–	﹤0.01%	1621
2026 Q1	$1.12K	Buy	+60	New	+$994	﹤0.01%	1633

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CVA Family Office's MLTX Position: Q2 2026 in Review

CVA Family Office held its MoonLake Immunotherapeutics (MLTX) position steady in Q2 2026 at 60 shares worth $1.17K. The position accounts for ﹤0.01% of the portfolio, ranked #1621.

CVA Family Office first reported a position in MLTX in Q1 2026 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

CVA Family Office held 60 shares of MoonLake Immunotherapeutics worth $1.17K as of Q2 2026.
CVA Family Office left its MoonLake Immunotherapeutics share count unchanged in Q2 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1621 holding.
CVA Family Office first reported a position in MoonLake Immunotherapeutics in Q1 2026 and has held it in 2 quarters since.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.